Trials / Conditions / Intra-Abdominal Infections

Intra-Abdominal Infections

18 registered clinical trials studyying Intra-Abdominal Infections — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Gelaspan vs Crystalloid Therapy in Sepsis NCT07172451	Shanghai Zhongshan Hospital	Phase 4
Recruiting	Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers NCT07207291	Joincare Pharmaceutical Group Industry Co., Ltd	Phase 1
Completed	Capillary Leak Index as a Prognostic Indicator for Post-Operative Abdominal Sepsis in Critically Ill Patients NCT06901544	Ain Shams University	—
Not Yet Recruiting	Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI NCT06633718	Qilu Pharmaceutical Co., Ltd.	Phase 3
Withdrawn	Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED) NCT05639504	Inflammatix	—
Completed	Gut Microbiota Analysis in IAI Patients With Sepsis-associated Liver Dysfunction NCT05628493	Chinese Medical Association	—
Withdrawn	Procalcitonin Guided Antibiotic Therapy NCT04240288	Columbia University	N/A
Completed	TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspec NCT04094818	Inflammatix	—
Completed	Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2) NCT03997929	Central Hospital, Nancy, France	—
Completed	Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI) NCT03358576	Iterum Therapeutics, International Limited	Phase 3
Terminated	LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection ( NCT03354754	Novartis Pharmaceuticals	Phase 2
Completed	Abdominal SepsiS Study: Epidemiology of Etiology and Outcome NCT02442596	European Society of Intensive Care Medicine	—
Completed	Tygacil Drug Use Investigation NCT01789905	Pfizer	—
Completed	Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/ NCT01506271	Merck Sharp & Dohme LLC	Phase 2
Completed	A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection NCT01473836	Pfizer	Phase 3
Completed	Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care NCT01431326	Daniel Benjamin	—
Completed	A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdomina NCT00965848	Janssen-Cilag Ltd.,Thailand	Phase 4
Completed	Post-Authorization Study Evaluating Safety Of Tigecycline NCT00827541	Pfizer	—